Logo image of IDEX.OL

IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis

OSL:IDEX - Euronext Oslo - NO0013107490 - Common Stock - Currency: NOK

0.094  +0 (+2.06%)

Fundamental Rating

3

Taking everything into account, IDEX scores 3 out of 10 in our fundamental rating. IDEX was compared to 49 industry peers in the Electronic Equipment, Instruments & Components industry. IDEX may be in some trouble as it scores bad on both profitability and health. IDEX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IDEX had negative earnings in the past year.
In the past year IDEX has reported a negative cash flow from operations.
IDEX had negative earnings in each of the past 5 years.
IDEX had a negative operating cash flow in each of the past 5 years.
IDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFIDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

IDEX's Return On Assets of -120.44% is on the low side compared to the rest of the industry. IDEX is outperformed by 91.84% of its industry peers.
IDEX has a Return On Equity of -272.88%. This is amonst the worse of the industry: IDEX underperforms 89.80% of its industry peers.
Industry RankSector Rank
ROA -120.44%
ROE -272.88%
ROIC N/A
ROA(3y)-98.9%
ROA(5y)-118.43%
ROE(3y)-154.74%
ROE(5y)-172.01%
ROIC(3y)N/A
ROIC(5y)N/A
IDEX.OL Yearly ROA, ROE, ROICIDEX.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IDEX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDEX.OL Yearly Profit, Operating, Gross MarginsIDEX.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IDEX has more shares outstanding
IDEX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IDEX has a worse debt to assets ratio.
IDEX.OL Yearly Shares OutstandingIDEX.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
IDEX.OL Yearly Total Debt VS Total AssetsIDEX.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -41.49, we must say that IDEX is in the distress zone and has some risk of bankruptcy.
IDEX's Altman-Z score of -41.49 is on the low side compared to the rest of the industry. IDEX is outperformed by 87.76% of its industry peers.
IDEX has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.34, IDEX is in line with its industry, outperforming 57.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -41.49
ROIC/WACCN/A
WACC0.63%
IDEX.OL Yearly LT Debt VS Equity VS FCFIDEX.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

IDEX has a Current Ratio of 2.16. This indicates that IDEX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IDEX (2.16) is better than 71.43% of its industry peers.
A Quick Ratio of 0.85 indicates that IDEX may have some problems paying its short term obligations.
The Quick ratio of IDEX (0.85) is worse than 69.39% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 0.85
IDEX.OL Yearly Current Assets VS Current LiabilitesIDEX.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.78% over the past year.
IDEX shows a small growth in Revenue. In the last year, the Revenue has grown by 1.15%.
IDEX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 62.79% yearly.
EPS 1Y (TTM)39.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)1.15%
Revenue growth 3Y55.76%
Revenue growth 5Y62.79%
Sales Q2Q%-95.83%

3.2 Future

Based on estimates for the next years, IDEX will show a very strong growth in Earnings Per Share. The EPS will grow by 57.57% on average per year.
IDEX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 225.52% yearly.
EPS Next Y100%
EPS Next 2Y57.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year610.01%
Revenue Next 2Y225.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IDEX.OL Yearly Revenue VS EstimatesIDEX.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
IDEX.OL Yearly EPS VS EstimatesIDEX.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 0.5 -0.5 -1 -1.5 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

IDEX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 0.18 indicates a rather cheap valuation of IDEX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDEX indicates a rather cheap valuation: IDEX is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IDEX to the average of the S&P500 Index (22.10), we can say IDEX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.18
IDEX.OL Price Earnings VS Forward Price EarningsIDEX.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDEX.OL Per share dataIDEX.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

IDEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IDEX's earnings are expected to grow with 57.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.57%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IDEX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEX BIOMETRICS ASA

OSL:IDEX (3/7/2025, 7:00:00 PM)

0.094

+0 (+2.06%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-14 2025-05-14
Inst Owners7.55%
Inst Owner ChangeN/A
Ins Owners3.32%
Ins Owner ChangeN/A
Market Cap1.65M
Analysts82.86
Price Target13.24 (13985.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.18
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)0.52
Fwd EY552.32%
FCF(TTM)-11.03
FCFYN/A
OCF(TTM)-11.03
OCFYN/A
SpS0.8
BVpS3.54
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -120.44%
ROE -272.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.9%
ROA(5y)-118.43%
ROE(3y)-154.74%
ROE(5y)-172.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 0.85
Altman-Z -41.49
F-Score1
WACC0.63%
ROIC/WACCN/A
Cap/Depr(3y)14.15%
Cap/Depr(5y)22.77%
Cap/Sales(3y)5.79%
Cap/Sales(5y)49.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y100%
EPS Next 2Y57.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.15%
Revenue growth 3Y55.76%
Revenue growth 5Y62.79%
Sales Q2Q%-95.83%
Revenue Next Year610.01%
Revenue Next 2Y225.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.78%
OCF growth 3YN/A
OCF growth 5YN/A